CT scan
Cross-sectional imaging to assess tumour size, location, and nearby organs.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Assess the size of the tumor and lymph nodes.
- Becomes the basis for measuring therapeutic response.
Informs decisions
- Stadiums.
- Comparison of sizes in periodic evaluations.
How the test is done
The patient lies inside the scanner; Some examinations require a contrast agent.
- Sample type
- Not invasive
- Estimated result time
- Results can be read on the same day.
Limitations
- Requires consideration of kidney function when using contrast.
- Measurements may vary between readers.
Related
Cancer types
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Liver Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Colorectal Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Immunotherapy
Treatment category
Reason: Memerlukan pemeriksaan
- Oncology intervention (interventional radiology)
Treatment category
Reason: Memerlukan pemeriksaan
- Stomach Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Brain Cancer
Cancer type
Reason: Memerlukan pemeriksaan
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.